Talquetamab with pomalidomide or with teclistamab for relapsed or refractory multiple myeloma previously treated with an anti-CD38 antibody and lenalidomide

Talquetamab, in combination with pomalidomide (Tal+P) or with teclistamab (Tal+Tec), is in development for the treatment of relapsed or refractory multiple myeloma (RRMM) in patients who have previously received at least one prior therapy, including an anti-cluster of differentiation 38 (anti-CD38) antibody and lenalidomide therapy. Multiple myeloma (MM) is a type of blood cancer that is characterised by an abundance of abnormal immune cells, known as plasma cells, in the bone marrow (the spongy tissue at the centre of some bones that produces the body’s blood cells). MM affects several areas of the body, such as the spine, skull, pelvis and ribs, and symptoms may include persistent bone pain, tiredness, weakness, shortness of breath, repeated infections, unusual bleeding, and kidney problems. Outcomes for patients with disease progression is poor, therefore there is a need to develop new treatment options for RRMM.